Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: A systematic review

Virulence

Volumn 4, Issue 6, 2013, Pages

  Graham, Susan M ^a   Mwilu, Regina ^a   Conrad Liles, W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biomarker; Coagulation; Endothelium; HIV; Vascular dysfunction

Indexed keywords

ABACAVIR; BIOLOGICAL MARKER; D DIMER; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PADGEM PROTEIN; PENTOXIFYLLINE; PLACEBO; PLASMINOGEN ACTIVATOR; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SALSALATE; TELMISARTAN; TENOFOVIR; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ZIDOVUDINE;

ARTERIAL STIFFNESS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FRAMINGHAM RISK SCORE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; ANIMAL; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; VASCULAR ENDOTHELIUM; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; BIOLOGICAL MARKERS; BLOOD COAGULATION; ENDOTHELIUM, VASCULAR; HIV INFECTIONS; HIV-1; HUMANS; PROGNOSIS;

EID: 84882625466     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.25221     Document Type: Review

References (47)

1. Centers for Disease Control and Prevention (CDC). HIV surveillance--United States, 1981-2008. MMWR Morb Mortal Wkly Rep 2011; 60:689-93; PMID:21637182
2. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-9; PMID:16741877; http://dx.doi. org/10.1086/505147
3. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22:2409-18; PMID:19005264; http://dx.doi. org/10.1097/QAD.0b013e3283174636
4. Lifson AR, Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, et al.; INSIGHT Cause of Death Writing Group. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials 2008; 9:177-85; PMID:18547904; http://dx.doi.org/10.1310/hct0903-177
5. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172; PMID:19171560; http:// dx.doi.org/10.1136/bmj.a3172
6. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al.; Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53:1130-9; PMID:21998280; http://dx.doi. org/10.1093/cid/cir626
7. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 2010; 5:498-503; PMID:20978393; http://dx.doi.org/10.1097/ COH.0b013e32833ed6f4
8. Dubé MP, Sattler FR. Inflammation and complications of HIV disease. J Infect Dis 2010; 201:1783-5; PMID:20446849; http://dx.doi.org/10.1086/652751
9. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M; Swiss HIV Cohort Study. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185:456-62; PMID:11865397; http://dx.doi.org/10.1086/338572
10. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al.; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203; PMID:18942885; http://dx.doi.org/10.1371/ journal.pmed.0050203
11. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23:1841-9; PMID:19455012; http://dx.doi. org/10.1097/QAD.0b013e32832d3b85
12. Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, et al.; D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006; 7:218-30; PMID:16630034; http://dx.doi. org/10.1111/j.1468-1293.2006.00362.x
13. Fourie C, van Rooyen J, Pieters M, Conradie K, Hoekstra T, Schutte A. Is HIV-1 infection associated with endothelial dysfunction in a population of African ancestry in South Africa? Cardiovasc J Afr 2011; 22:134-40; PMID:21713302; http://dx.doi. org/10.5830/CVJA-2010-056
14. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation 2006; 113:e72-5; PMID:16476853; http://dx.doi. org/10.1161/CIRCULATIONAHA.105.595520
15. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation. Circulation 2006; 113:e152-5; PMID:16490825; http://dx.doi.org/10.1161/ CIRCULATIONAHA.105.595538
16. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part III: biomarkers of oxidative stress and angiogenic growth factors. Circulation 2006; 113:e289-92; PMID:16505179; http://dx.doi.org/10.1161/ CIRCULATIONAHA.105.595546
17. Calza L, Pocaterra D, Pavoni M, Colangeli V, Manfredi R, Verucchi G, et al. Plasma levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIVpositive patients versus 51 HIV-negative healthy controls. J Acquir Immune Defic Syndr 2009; 50:430-2; PMID:19322038; http://dx.doi.org/10.1097/ QAI.0b013e31819a292c
18. Gattegno L, Bentata-Peyssare M, Gronowski S, Chaouche K, Ferriere F. Elevated concentrations of circulating intercellular adhesion molecule 1 (ICAM-1) and of vascular cell adhesion molecule 1 (VCAM-1) in HIV-1 infection. Cell Adhes Commun 1995; 3:179-85; PMID:8846020; http://dx.doi. org/10.3109/15419069509081285
19. Lichtner M, Cuomo MR, Rossi R, Strano S, Massetti AP, Mastroianni CM, et al. Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment. Atherosclerosis 2009; 204:e1-3; PMID:19185298; http://dx.doi. org/10.1016/j.atherosclerosis.2008.12.025
20. Bernal E, Marín I, Muñoz A, Sabán J, Vicente-Vera T, Cano A. High prevalence of subclinical atherosclerotic disease in Spanish HIV-infected patients with low cardiovascular risk. AIDS Patient Care STDS 2011; 25:269-72; PMID:21466379; http://dx.doi. org/10.1089/apc.2011.0014
21. Kline ER, Sutliff RL. The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med 2008; 56:752-69; PMID:18525451
22. Vlachopoulos C, Xaplanteris P, Sambatakou H, Mariolis E, Bratsas A, Christoforatou E, et al. Acute systemic inflammation induced by influenza A (H1N1) vaccination causes a deterioration in endothelial function in HIV-infected patients. HIV Med 2011; 12:594-601; PMID:21645196; http://dx.doi.org/10.1111/j.1468-1293.2011.00935.x
23. Ucciferri C, Falasca K, Mancino P, Di Iorio A, Vecchiet J. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan. Eur Rev Med Pharmacol Sci 2012; 16:491-8; PMID:22696876
24. Hileman CO, Carman TL, Gripshover BM, O'Riordan M, Storer NJ, Harrill DE, et al. Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults. AIDS 2010; 24:1958-61; PMID:20613460; http://dx.doi. org/10.1097/QAD.0b013e32833c3251
25. Gupta SK, Johnson RM, Mather KJ, Clauss M, Rehman J, Saha C, et al. Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study. AIDS 2010; 24:1377-80; PMID:20559042; http://dx.doi.org/10.1097/ QAD.0b013e3283396024
26. Tungsiripat M, El-Bejjani D, Rizk N, Dogra V, O'Riordan MA, Ross AC, et al. Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. AIDS Res Hum Retroviruses 2011; 27:295-302; PMID:20969457; http://dx.doi.org/10.1089/ aid.2010.0187
27. van Vonderen MG, Hassink EA, van Agtmael MA, Stehouwer CD, Danner SA, Reiss P, et al. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis 2009; 199:1186-94; PMID:19275490; http://dx.doi.org/10.1086/597475
28. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, et al.; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200:973-83; PMID:19678756; http://dx.doi. org/10.1086/605447
29. Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher L, Badralmaa Y, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24:1509-17; PMID:20505494; http://dx.doi.org/10.1097/ QAD.0b013e32833ad914
30. Musselwhite LW, Sheikh V, Norton TD, Rupert A, Porter BO, Penzak SR, et al. Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV. AIDS 2011; 25:787-95; PMID:21412059; http://dx.doi. org/10.1097/QAD.0b013e3283453fcb
31. Sipsas NV, Sfikakis PP, Touloumi G, Pantazis N, Choremi H, Kordossis T. Elevated serum levels of soluble immune activation markers are associated with increased risk for death in HAART-naive HIV-1-infected patients. AIDS Patient Care STDS 2003; 17:147-53; PMID:12737638; http://dx.doi. org/10.1089/108729103321619755
32. Francisci D, Falcinelli E, Belfiori B, Petito E, Fierro T, Baldelli F, et al. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction. AIDS Patient Care STDS 2011; 25:567-9; PMID:21851265; http:// dx.doi.org/10.1089/apc.2011.0184
33. Jong E, Louw S, van Gorp EC, Meijers JC, ten Cate H, Jacobson BF. The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thromb Haemost 2010; 104:1228-34; PMID:20886182; http://dx.doi.org/10.1160/TH10-04-0233
34. Aukrust P, Bjørnsen S, Lunden B, Otterdal K, Ng EC, Ameln W, et al. Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy. Thromb Haemost 2000; 84:183-7; PMID:10959687
35. Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, et al.; VACS Project Team. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54:984-94; PMID:22337823; http://dx.doi. org/10.1093/cid/cir989
36. Schved JF, Gris JC, Arnaud A, Martinez P, Sanchez N, Wautier JL, et al. von Willebrand factor antigen, tissuetype plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator. J Lab Clin Med 1992; 120:411-9; PMID:1517688
37. Gresele P, Falcinelli E, Sebastiano M, Baldelli F. Endothelial and platelet function alterations in HIV-infected patients. Thromb Res 2012; 129:301-8; PMID:22192157; http://dx.doi.org/10.1016/j. thromres.2011.11.022
38. Rectenwald JE, Myers DD Jr., Hawley AE, Longo C, Henke PK, Guire KE, et al. D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost 2005; 94:1312-7; PMID:16411411
39. Suy A, Martínez E, Coll O, Lonca M, Palacio M, de Lazzari E, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20:59-66; PMID:16327320; http://dx.doi.org/10.1097/01. aids.0000198090.70325.bd
40. Graham SM, Rajwans N, Jaoko W, et al. Endothelial activation biomarkers increase after HIV-1 acquisition: plasma VCAM-1 predicts disease progression. AIDS 2013; In press
41. Graham SM, Rajwans N, Tapia K, Jaoko W, Estambale BB, McClelland RS, et al. A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy. BMC INfect Dis 2013; 13:263; PMID: 23734875; http://dx.doi. org/10.1186/1471-2334-13-263
42. Ozturk B, Tutuncu E, Kuscu F, Gurbuz Y, Sencan I, Tuzun H. Evaluation of factors predictive of the prognosis in Crimean-Congo hemorrhagic fever: new suggestions. Int J Infect Dis 2012; 16:e89-93; PMID:22154082; http://dx.doi.org/10.1016/j. ijid.2011.06.005
43. Zangerle R, Fuchs D, Sarcletti M, Gallati H, Reibnegger G, Wachter H, et al. Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infection. Clin Immunol Immunopathol 1994; 72:328-34; PMID:7914841; http://dx.doi. org/10.1006/clin.1994.1149
44. Greenwood AJ, Hughes J, Wallace G, Seed P, Stanford MR, Graham EM. Soluble intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) in patients with HIV/AIDS does not appear to correlate with cytomegalovirus retinitis. Int J STD AIDS 1998; 9:713-4; PMID:9863589
45. Renwick N, Weverling GJ, Brouwer J, Bakker M, Schulz TF, Goudsmit J. Vascular endothelial growth factor levels in serum do not increase following HIV type 1 and HHV8 seroconversion and lack correlation with AIDS-related Kaposi's sarcoma. AIDS Res Hum Retroviruses 2002; 18:695-8; PMID:12167275; http:// dx.doi.org/10.1089/088922202760072302
46. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-8; PMID:15023877; http://dx.doi.org/10.1161/01. CIR.0000124480.32233.8A
47. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, et al.; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96; PMID:17135583; http://dx.doi.org/10.1056/NEJMoa062360